Lifileucel: Difference between revisions
CSV import |
CSV import |
||
| Line 41: | Line 41: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Revision as of 23:34, 10 February 2025
Lifileucel is an investigational immunotherapy treatment designed for patients with advanced melanoma. It is a type of adoptive cell transfer (ACT) therapy that utilizes tumor-infiltrating lymphocytes (TILs) to target and destroy cancer cells.
Mechanism of Action
Lifileucel works by harnessing the body's own immune system to fight cancer. The process begins with the extraction of TILs from a patient's tumor. These TILs are then expanded and activated in a laboratory setting before being reintroduced into the patient's body. Once administered, the TILs seek out and attack cancer cells, leveraging their natural ability to recognize and destroy malignant cells.
Clinical Development
Lifileucel is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase studies have shown promising results, with some patients experiencing significant tumor reduction. The therapy is being developed by Iovance Biotherapeutics, a company specializing in TIL-based therapies.
Administration
The administration of Lifileucel involves several steps: 1. **Tumor Harvesting**: A sample of the patient's tumor is surgically removed. 2. **TIL Expansion**: The TILs are isolated from the tumor sample and expanded in a laboratory. 3. **Preconditioning**: The patient undergoes a lymphodepleting regimen to prepare the body for the infusion of TILs. 4. **TIL Infusion**: The expanded TILs are infused back into the patient. 5. **Post-Infusion Care**: The patient may receive supportive care and monitoring to manage any side effects.
Potential Side Effects
As with any immunotherapy, Lifileucel may cause side effects. Common side effects include fever, chills, fatigue, and cytokine release syndrome (CRS). More severe side effects can occur and require careful monitoring and management by healthcare professionals.
Future Directions
Research is ongoing to explore the potential of Lifileucel in treating other types of cancer beyond melanoma. Additionally, combination therapies involving Lifileucel and other immunotherapies or targeted treatments are being investigated to enhance its efficacy.
Related Pages
- Immunotherapy
- Melanoma
- Adoptive cell transfer
- Tumor-infiltrating lymphocytes
- Iovance Biotherapeutics
- Cytokine release syndrome
References
<references group="" responsive="1"></references>
External Links
